Clinical Trial Detail

NCT ID NCT02501096
Title Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eisai Inc.
Indications

melanoma

endometrial cancer

lung non-small cell carcinoma

renal cell carcinoma

transitional cell carcinoma

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Lenvatinib

Age Groups: adult

No variant requirements are available.